Welcome to LookChem.com Sign In|Join Free

CAS

  • or

250264-28-9

Post Buying Request

250264-28-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

250264-28-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 250264-28-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,0,2,6 and 4 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 250264-28:
(8*2)+(7*5)+(6*0)+(5*2)+(4*6)+(3*4)+(2*2)+(1*8)=109
109 % 10 = 9
So 250264-28-9 is a valid CAS Registry Number.

250264-28-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-Chloro-1,8-naphthyridin-2(1H)-one

1.2 Other means of identification

Product number -
Other names 2-hydroxy-5-carboxymethylmuconate semialdehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:250264-28-9 SDS

250264-28-9Relevant articles and documents

Synthesis of 1,8-naphthyridine derivatives: Potential antihypertensive agents - Part VIII

Ferrarini, Pier Luigi,Mori, Claudio,Calderone, Vincenzo,Calzolari, Lorella,Nieri, Paola,Saccomanni, Giuseppe,Martinotti, Enrica

, p. 505 - 513 (1999)

A series of (ethoxycarbonylpiperazinyl)- and piperazinyl- 1,8- naphthyridine derivatives, variously substituted, has been synthesized and pharmacologically investigated for anthihypertensive activity. Some of them exhibited a significant and prolonged decrease of the mean arterial pressure (MAP) on spontaneously hypertensive rats. On the basis of the pharmacological results, no structure-activity relationship can be deduced at this time. Moreover, the most active compound 4e, was investigated by means of in vitro pharmacological functional studies and in vivo, as a diuretic agent, to determine a possible mechanism of the antihypertensive activity, which results in a probably non-competitive antagonism against α1 vascular adrenoceptors. This mechanism was also shown by the compounds 8 and 13.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 250264-28-9